Cargando…
Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection
Invasive pulmonary Aspergillosis is a leading cause of morbidity and mortality in immunosuppressed patients and treatment outcomes using oral antifungal triazoles remain suboptimal. Here we show that combining topical treatment using PC945, a novel inhaled triazole, with systemic treatment using kno...
Autores principales: | Colley, Thomas, Sehra, Gurpreet, Daly, Leah, Kimura, Genki, Nakaoki, Takahiro, Nishimoto, Yuki, Kizawa, Yasuo, Strong, Pete, Rapeport, Garth, Ito, Kazuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603190/ https://www.ncbi.nlm.nih.gov/pubmed/31263150 http://dx.doi.org/10.1038/s41598-019-45890-w |
Ejemplares similares
-
In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice
por: Kimura, Genki, et al.
Publicado: (2017) -
Anti-fungal activity of a novel triazole, PC1244, against emerging azole-resistant Aspergillus fumigatus and other species of Aspergillus
por: Colley, Thomas, et al.
Publicado: (2019) -
In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection
por: Colley, Thomas, et al.
Publicado: (2017) -
In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris
por: Rudramurthy, Shivaprakash M, et al.
Publicado: (2019) -
Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent
por: Cass, Lindsey, et al.
Publicado: (2020)